

ESPACOMP Medication Adherence Reporting Guideline (EMERGE)

De Geest, S.; Zullig, Leah L. ; Dunbar-Jacob, Jacqueline; Helmy, Remon;
Hughes, Dyfrig; Wilson, Ira; Vrijens, Bernard

Annals of Internal Medicine

DOI:

[10.7326/M18-0543](https://doi.org/10.7326/M18-0543)

Published: 03/07/2018

Peer reviewed version

[Cyswllt i'r cyhoeddiad / Link to publication](#)

Dyfyniad o'r fersiwn a gyhoeddwyd / Citation for published version (APA):

De Geest, S., Zullig, L. L., Dunbar-Jacob, J., Helmy, R., Hughes, D., Wilson, I., & Vrijens, B. (2018). ESPACOMP Medication Adherence Reporting Guideline (EMERGE). *Annals of Internal Medicine*, 169(1), 30-35. <https://doi.org/10.7326/M18-0543>

Hawliau Cyffredinol / General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

ESPACOMP Medication Adherence Reporting Guideline (EMERGE)

Sabina De Geest, Leah L Zullig, Jacqueline Dunbar-Jacob, Remon Helmy, Dyfrig A Hughes,
Ira B Wilson*, Bernard Vrijens*

*Joint last authorship

Sabina De Geest, PhD, RN: Professor, Nursing Science, Chair Department of Public Health, Faculty of Medicine, University of Basel, 4056 Basel, Switzerland & Professor. Academic Centre for Nursing and Midwifery, Department of Public Health and Primary Care, KU Leuven, 3000 Leuven, Belgium

Leah L Zullig, PhD, MPH: Assistant Professor, Center for Health Services Research in Primary Care, Durham Veterans Affairs Health Care System, Durham, North Carolina 27701, USA & Department of Population Health Sciences, School of Medicine, Duke University, Durham, North Carolina 27707, USA

Jacqueline Dunbar-Jacob, PhD, RN: Distinguished Service Professor & Dean. School of Nursing, University of Pittsburgh, Pittsburgh, 3500 Victoria Building, Pittsburgh PA 15261, USA

Remon Helmy, MSc: Research assistant, Nursing Science, Department of Public Health, Faculty of Medicine, University of Basel, 4056 Basel, Switzerland

Dyfrig A Hughes, MRPharmS, PhD: Professor and co-director. Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, Gwynedd, North Wales LL57 2PZ, UK

Ira B Wilson, MD, PhD: Professor and Chair. Department of Health Services, Policy & Practice, Brown University School of Public Health, Providence, Rhode Island 02912, USA

Bernard Vrijens, PhD: Invited professor. Department of Public Health, University of Liège, 4000 Liège, Belgium & Chief science officer. AARDEX Group, 4600 Visé, Belgium

Correspondence and reprint request to: Sabina De Geest, Nursing Science, Department of Public Health, Faculty of Medicine, University of Basel, 4056 Basel, Switzerland Tel: +41 79 3741081; Fax: +41 61 2070951; Email: sabina.degeest@unibas.ch

Keywords: medication adherence, health research reporting guidelines, Delphi study

Word count, excluding title page, abstract, references, figures and tables: 1971.

34 ABSTRACT

35 Medication adherence-related research applies observational, interventional and/or implementation
36 science approaches spanning multiple disciplines to assess or manage medication adherence. This
37 demands coherent conceptualization, valid methods, appropriate analyses, and complete, accurate
38 reporting. To ensure reliable reporting, the European Society for Patient Adherence, Compliance and
39 Persistence (ESPACOMP) Medication Adherence Reporting Guideline (EMERGE) recommends
40 standard reporting approaches based on an accepted taxonomy.

41 This guideline results from a literature review, a reactive e-Delphi study with 26 international
42 multidisciplinary medication adherence experts, and feedback from the ESPACOMP membership. It
43 is designed to supplement existing guidelines for health research reporting, and structured around 4
44 minimum reporting criteria and 17 items reflecting best reporting practice. By enhancing and
45 harmonizing research reporting, EMERGE aims to advance research and, ultimately, patient
46 outcomes.

CHALLENGES AND SHORTCOMINGS IN MEDICATION ADHERENCE REPORTING

Medication non-adherence is a major public health problem(1, 2) with significant health and economic consequences.(1-4) For many conditions, taking medications as prescribed is crucial to achieve optimal outcomes.(5-7) Despite more than 50 years of research, the evidence base for effective interventions that can be implemented in routine clinical care remains limited.(8, 9)

Medication adherence-related research applies observational, interventional and/or implementation science approaches across disciplines including, but not limited to medicine, pharmacy, nursing, behavioral science, sociology, pharmacometrics, biostatistics and health economics.(10) Unfortunately, inadequate research reporting often hampers interpretation of findings, complicates data abstraction for meta-analyses and prevents study replication. Common problems of reporting include unclear, inconsistent definitions;(11-14) inadequate measurement of adherence outcomes;(7, 14, 15) suboptimal methods of analysis;(11-14) insufficiently detailed descriptions of intervention delivery settings;(15) and scant theoretical underpinnings.(16)

Previous efforts to improve adherence research reporting standards(11, 17-20), have resulted in guidelines and recommendations that overlap with existing health research reporting guidelines, e.g., CONSolidated Standards of Reporting Trials (CONSORT),(21) STrengthening the Reporting of OBservational studies in Epidemiology (STROBE),(22) Standards for Reporting Implementation Studies (StaRI) Statement (StaRI).(23) These recommendations only indirectly pertain to medication adherence research,(17, 19) include no clear conceptualization of medication adherence(11, 17, 19, 20) and focus on research methods rather than reporting.(11, 19, 20)

Weighing these shortcomings against evidence that guidelines endorsed by professional societies and journals enhance overall health research reporting,(24-28) the European Society for Patient Adherence, COMPLiance, and Persistence (ESPACOMP, www.espacomp.eu, accessed: April 30th, 2018) developed the ESPACOMP Medication Adherence Reporting Guideline (EMERGE). Grounded in the conceptualization of medication adherence provided by the previously-reported taxonomy,(10) EMERGE aims to complement existing health research reporting guidelines, increasing the transparency and consistency of reporting by guiding researchers through processes specifically relevant to medication adherence, as well as to those for which it is a variable of interest.

Taxonomy for medication adherence

EMERGE adopts the previously-reported taxonomy(10) which defines medication adherence as “the process by which patients take their medications as prescribed,” consisting of three interrelated yet distinct phases: (A) **initiation**; (B) **implementation**; and (C) **persistence (figure 1)**. Non-adherence to

medications can occur in any of these phases, e.g., late, incomplete, or non-initiation of the prescribed treatment, sub-optimal implementation of the dosing regimen (e.g., late, skipped, extra or reduced doses, drug holidays) or early discontinuation (non-persistence). Each phase poses different methodological challenges related to how medication use is operationally defined, measured, and analyzed.

DEVELOPMENT OF EMERGE

EMERGE was developed in accordance with recommendations for health research reporting guideline developers(29) of the Enhancing the QUALity and Transparency Of health Research (EQUATOR) network (www.equator-network.org, accessed: April 30th, 2018). The methods for developing EMERGE have been previously published.(30) Briefly, a steering committee comprised of 7 members of ESPACOMP (SDG, LLZ, JDJ, RH, DAH, IBW, BV) led the project. The committee first convened in Prague, Czech Republic in 2015, followed by 4 feedback rounds via email and conference calls in 2016. Their discussion of a literature review of published adherence guidelines and a further review of existing health research reporting guidelines(21-23, 31) yielded an initial pool of 26 items (i.e., statements) organized according to the sections of the most used health research reporting guidelines (i.e., CONSORT, STROBE). To avoid redundancy and facilitate EMERGE's applicability across the various study designs, the committee considered overlap with existing guidelines throughout the development process.(30)

The initial 26-item pool was the basis of two rounds of reactive e-Delphi surveys.(32, 33) A purposive sample of 45 international experts (across 15 countries, 6 continents), representing diverse disciplines and fields engaged in medication adherence research was selected and invited to participate (i.e., 17 in clinical research, 14 in health services research, 13 in public health, 11 in medicine, 9 in behavioral medicine/health psychology, 6 in journal editing, 5 in health policy, 5 in pharmacoepidemiology, 5 in statistics, 4 in nursing, 4 in pharmacy / pharmaceutical sciences, 3 in clinical pharmacology, 2 in the pharmaceutical industry and 6 in other fields; on average, experts belonged to about 4 disciplines). Of the 45 experts, 29 participated in the first round (64% response rate). They evaluated each item for relevance and clarity, and could comment, suggest further items and/or modify the initial items. Guided by pre-defined rules(30) as well as by qualitative comments received from the survey experts, the steering committee reviewed and discussed the first-round e-Delphi results during a meeting in Húsafell, Iceland in July 2016.

Based on the agreed criteria, all 26 items initially evaluated in the first Delphi round were judged relevant (mean 91%, SD 5%, range: 79%-97%) and clear (mean 84%, SD 10% range: 59%-97%). Nevertheless, the experts' qualitative comments and subsequent discussion in the steering

committee presented opportunities to optimize the wording of several items. The committee consequently chose to exclude 5 items due to redundancy or inconsistency with other EMERGE items, or with items from the main reporting guidelines.

The remaining 21 items entered the second e-Delphi round, during which 26 of the 29 (90%) experts who participated in the first round re-rated the items for relevance and clarity. All items again cleared the threshold for relevance (mean 93%, range: 85%-100%) and clarity (mean 90%, range: 73%-100%). The qualitative comments allowed fine-tuning of several items' wording, resulting in the 21-item list presented at the annual ESPACOMP conference in Lisbon, Portugal in November 2016 and approved by a formal vote of all members.

ESPACOMP MEDICATION ADHERENCE REPORTING GUIDELINE (EMERGE)

EMERGE consists of 21 items organized in 2 sections (see table 1). The first section includes 4 items outlining the *minimum reporting criteria* for medication adherence research. The following criteria need to be specified clearly: (1) each phase of medication adherence studied (i.e., initiation, implementation, persistence); (2) a precise operational/working definition of each of the phases of medication adherence examined; (3) the methods of adherence measurement used for each phase, along with information on performance of the measure (i.e., validity, reliability, potential bias); and (4) the results of the analysis relevant to each phase.

The second section of the guideline consists of 17 items that provide more detailed and specific information on the reporting of medication adherence. These are organized according to the reporting guidelines for experimental and observational studies (i.e., CONSORT, STROBE) (table 1). Building on the minimum reporting criteria, these items further highlight the importance of considering and distinguishing between the 3 phases of medication adherence (e.g., item 6: background/introduction; item 8: study objectives or hypotheses; item 15: statistical analysis; items 19 & 21: discussion). Other items address areas that are often under- or unreported in adherence research. Item 7, for instance, addresses the need to clarify the rationale and/or framework guiding the study. Item 9 addresses information relevant to the setting where the adherence study was conducted (e.g., relevant characteristics of the healthcare system, healthcare organization and healthcare team); and item 11 requests information on routine care related to the management of medication adherence. For intervention studies (item 13), descriptions of both intervention and comparator groups are requested. Interventions should be described (if relevant) in the context of specified levels of the healthcare system (i.e., patient/caregiver, healthcare provider, healthcare organization and healthcare system). Further methodological details are requested pertaining to sampling (item 10 asks whether medication adherence is an eligibility criterion) and measurement

(item 12 addresses the potential impact of the adherence measure used on medication adherence). Information requested on statistical methods distinguishes between medication adherence as an outcome measure (item 15) and its use as an explanatory variable (item 16). Item 14 – an item relevant to implementation science – asks for information (when applicable) on any implementation strategy(34) that contributes to translation of a medication adherence intervention into clinical practice. EMERGE also reminds authors to include details in their results sections of possible links between non-participation and/or dropout either with medication non-adherence (item 17) or with sample characteristics relevant to it (item 18).

[Please insert Table 1 here]

DISCUSSION

The ESPACOMP Medication Adherence Reporting Guideline (EMERGE) was developed to help researchers improve the quality of their reporting of medication adherence research, as this type of research is often methodologically weak (8, 35, 36) and suboptimally reported (11-13). While EMERGE has the advantage of being applicable to multiple study designs and methods focusing on medication adherence, its use will involve authors combining EMERGE items with other appropriate guidelines for health research reporting (e.g., STROBE, CONSORT, STaRi).

EMERGE was developed through a consensus-based process involving a multidisciplinary group of international medication adherence experts. Using the Delphi surveys, these experts provided two rounds of feedback on the relevance and clarity of each included item. In addition to enhancing EMERGE's relevance across diverse settings, their cooperation will facilitate guideline implementation.

One of EMERGE's major strengths is its grounding in a medication adherence conceptualization provided by a robust taxonomy.(10) Since its initial publication, this taxonomy, distinguishing between 3 phases of adherence (i.e., initiation, implementation, persistence), has greatly benefitted the field of medication adherence research,(37, 38) and has been broadly adopted and widely cited.(39) EMERGE highlights the need to acknowledge and specify each of these 3 phases as being distinct parts of the process by which patients manage their medication regimens, that require specific considerations regarding their conceptualization, definition, measurement and analysis.

EMERGE items – with the 4 minimum reporting criteria at their core – reflect essential yet often poorly handled or omitted elements of medication adherence research reporting. This includes the omission or suboptimal definition of key terms,(7, 11-13) the use of suboptimal measures,(15) and the use of inappropriate analytical methods.(11-13) EMERGE also highlights the need for other

relevant and often neglected aspects of adherence research reporting, e.g., a clearly-explained rationale or framework(16) and detailed information on the healthcare setting, including routine care.(15)

EMERGE includes an item relevant to implementation science which is complementary to the STaRi reporting guideline,(23) in recognition of the importance of this discipline in advancing the field of medication adherence. While several promising interventions have been developed to improve adherence,(8, 35, 40) none have proved easy to implement in clinical practice. We do not suggest that every study can or should include an implementation component, but encourage researchers to plan studies with an eye towards potential implementation and sustainability.

The main limitation affecting EMERGE's development process is its primary focus on quantitative methodologies. However, the 4 minimum reporting criteria can also support qualitative and mixed-methods research in guaranteeing that the research's focus and relevant methodological aspects are aligned with the adherence taxonomy.(10) Additionally, although initial user testing demonstrated its easy applicability in combination with the main reporting guidelines, the advised combination of EMERGE with other reporting guidelines might initially seem challenging. Moreover, while following the 21 EMERGE items will yield thorough reporting of all matters common to medication adherence research, journal word count limits may sometimes restrict full reporting. Possible solutions include pre-publishing detailed methodologies and protocols and/or providing online-only supplements/appendices. Finally, although efforts were made to guarantee representation of all continents, there were fewer people from African and Asian countries in the international Delphi expert team.

In addition to this article, dissemination and use of the EMERGE guidelines will be enhanced by information available on the EQUATOR webpage (www.equator-network.org, accessed: April 30th, 2018) and the ESPACOMP website (www.espacomp.eu/emerge, accessed: April 30th, 2018), and endorsed by a range of related journals and professional organizations. ESPACOMP will support regular updates of EMERGE to ensure timely propagation of lessons learned from its use, along with new developments in medication adherence science.

CONCLUSION

Implementation of ESPACOMP Medication Adherence Reporting Guideline (EMERGE) is expected to enhance the quality of medication adherence research reporting via standardization, reducing research waste, accelerating progress in this and related fields, and ultimately, improving patient outcomes.

209 **ROLE OF THE FUNDING SOURCE**

210 The study was funded by ESPACOMP. As the EMERGE steering committee is composed entirely of
211 ESPACOMP members, they took the sole lead in designing EMERGE, in writing this paper, and in
212 submitting it for publication.

213

Acknowledgements

DA Hughes is supported by the Medical Research Council North West Hub for Trials Methodology Research (NWHTMR Reference number MR/K025635/1).

LL Zullig is supported by a VA Health Services Research and Development (HSR&D) Career Development Award (CDA 13-025).

We thank ESPACOMP for the support in developing EMERGE.

We thank the EMERGE expert panel (persons agreeing to be mentioned by name) for their participation in the two Delphi survey rounds: **Darren Ashcroft** (University of Manchester - Manchester, UK); **Anne Beal** (Sanofi - Paris, France); **Terrence Blaschke** (Stanford University - Stanford, California, USA, the Bill and Melinda Gates Foundation - Seattle, Washington, USA, and the University of California - San Francisco, California, USA); **Hayden Bosworth** (Duke University, Durham, North Carolina, USA & Durham VA Medical Center - Durham, North Carolina, USA); **Rhiannon Braund** (School of Pharmacy, University of Otago - Dunedin, New Zealand); **Timothy Chen** (University of Sydney - Sydney, New South Wales, Australia); **Niteesh Choudhry** (Brigham and Women's Hospital, Harvard Medical School - Boston, Massachusetts, USA); **Robyn Gallagher** (University of Sydney - Sydney, New South Wales, Australia); **Tracy Glass** (Swiss Tropical and Public Health Institute, University of Basel - Basel, Switzerland); **R. Brian Haynes** (McMaster University - Hamilton, Ontario, Canada); **Tiny Jaarsma** (Faculty of Medicine and Health Sciences, Linköping University - Linköping, Sweden and the Mary MacKillop Institute for Health Research, Australian Catholic University - Melbourne, Australia); **Ashraf Kagee** (Stellenbosch University - Stellenbosch, South Africa); **Przemyslaw Kardas** (Medical University of Lodz - Lodz, Poland); **Jocelyne Moisan** (Faculté de pharmacie de l'Université Laval and the Centre de recherche du CHU de Québec-Université Laval - Laval, Québec, Canada); **Donald Morisky** (University of California - Los Angeles, California, USA); **Andrew Mujugira** (Makerere University School of Public Health - Kampala, Uganda and the University of Washington - Seattle, Washington, USA); **Phillip Newton** (Western Sydney University - Sydney, New South Wales, Australia); **Habib Omari** (Kilimanjaro Christian Medical Center - Moshi, Tanzania); **Lars Osterberg** (Stanford University School of Medicine - Stanford, California, USA); **Cynthia Rand** (Johns Hopkins School of Medicine - Baltimore, Maryland, USA); **Todd Rupp** (Rush University - Chicago, Illinois, USA); **Helady Sanders-Pinheiro** (Federal University of Juiz de Fora - Juiz de Fora, Brazil); **Eyal Schwartzberg** (Pharmaceutical & Enforcement Divisions, Ministry of Health - Jerusalem, Israel & School of Pharmacy, Ben Gurion University - Beer Sheeba, Israel and the Arnold and Marie Schwartz College of Pharmacy, Long Island University - Brooklyn, New York, USA); **Michael Stirratt** (NIMH Division of AIDS Research - Rockville, Maryland, USA and NIH Adherence

247 Research Network - Bethesda, Maryland, USA); **Liset van Dijk** (Netherlands Institute for Health
248 Services Research - Utrecht, the Netherlands); **Eric Van Ganse** (Université Claude Bernard (Lyon 1) -
249 Lyon, France, the Lyon University Hospitals - Lyon, France and HESPER & PELyon Limited - Lyon,
250 France).

251 We thank **Chris Shultis** for editing this paper.

REFERENCES

1. Sabaté E. Adherence to long-term therapies: Evidence for action. Geneva: WHO; 2003.
2. Nunes V, Neilson J, O'Flynn N, Calvert N, Kuntze S, Smithson H, et al. Clinical Guidelines and Evidence Review for Medicines Adherence: involving patients in decisions about prescribed medicines and supporting adherence. National Institute for Health and Clinical Excellence: Guidance. London: Royal College of General Practitioners; 2009.
3. Iuga AO, McGuire MJ. Adherence and health care costs. *Risk Manag Healthc Policy*. 2014;7:35-44. doi: 10.2147/RMHP.S19801. PubMed PMID: 24591853; PubMed Central PMCID: PMC3934668.
4. Osterberg L, Blaschke T. Adherence to medication. *N Engl J Med*. 2005;353(5):487-97. doi: 10.1056/NEJMr050100. PubMed PMID: 16079372.
5. Simpson SH, Eurich DT, Majumdar SR, Padwal RS, Tsuyuki RT, Varney J, et al. A meta-analysis of the association between adherence to drug therapy and mortality. *BMJ*. 2006;333(7557):15. doi: 10.1136/bmj.38875.675486.55. PubMed PMID: 16790458; PubMed Central PMCID: PMC1488752.
6. Deshpande S, Quek RG, Forbes CA, de Kock S, Kleijnen J, Gandra SR, et al. A systematic review to assess adherence and persistence with statins. *Curr Med Res Opin*. 2017;33(4):769-78. doi: 10.1080/03007995.2017.1281109. PubMed PMID: 28076703.
7. Iglay K, Cartier SE, Rosen VM, Zarotsky V, Rajpathak SN, Radican L, et al. Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes. *Curr Med Res Opin*. 2015;31(7):1283-96. doi: 10.1185/03007995.2015.1053048. PubMed PMID: 26023805.
8. Nieuwlaat R, Wilczynski N, Navarro T, Hobson N, Jeffery R, Keenanasseril A, et al. Interventions for enhancing medication adherence. *Cochrane Database Syst Rev*. 2014(11):CD000011. doi: 10.1002/14651858.CD000011.pub4. PubMed PMID: 25412402.
9. Viswanathan M, Golin CE, Jones CD, Ashok M, Blalock SJ, Wines RC, et al. Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. *Ann Intern Med*. 2012;157(11):785-95. doi: 10.7326/0003-4819-157-11-201212040-00538. PubMed PMID: 22964778.
10. Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T, et al. A new taxonomy for describing and defining adherence to medications. *Br J Clin Pharmacol*. 2012;73(5):691-705. doi: 10.1111/j.1365-2125.2012.04167.x. PubMed PMID: 22486599; PubMed Central PMCID: PMC3403197.
11. Bender B, Milgrom H, Apter A. Adherence intervention research: what have we learned and what do we do next? *J Allergy Clin Immunol*. 2003;112(3):489-94. PubMed PMID: 13679805.
12. Demonceau J, Ruppar T, Kristanto P, Hughes DA, Fargher E, Kardas P, et al. Identification and assessment of adherence-enhancing interventions in studies assessing medication adherence through electronically compiled drug dosing histories: a systematic literature review and meta-analysis. *Drugs*. 2013;73(6):545-62. doi: 10.1007/s40265-013-0041-3. PubMed PMID: 23588595; PubMed Central PMCID: PMC3647098.
13. Oberje EJ, de Kinderen RJ, Evers SM, van Woerkum CM, de Bruin M. Cost effectiveness of medication adherence-enhancing interventions: a systematic review of trial-based economic evaluations. *Pharmacoeconomics*. 2013;31(12):1155-68. doi: 10.1007/s40273-013-0108-8. PubMed PMID: 24222477.
14. Gellad WF, Thorpe CT, Steiner JF, Voils CI. The myths of medication adherence. *Pharmacoepidemiol Drug Saf*. 2017. doi: 10.1002/pds.4334. PubMed PMID: 28994158.
15. MacDonald L, Chapman S, Syrett M, Bowskill R, Horne R. Improving medication adherence in bipolar disorder: A systematic review and meta-analysis of 30 years of intervention trials. *J Affect Disord*. 2016;194:202-21. doi: 10.1016/j.jad.2016.01.002. PubMed PMID: 26851552.

16. Conn VS, Enriquez M, Ruppar TM, Chan KC. Meta-analyses of Theory Use in Medication Adherence Intervention Research. *Am J Health Behav.* 2016;40(2):155-71. doi: 10.5993/AJHB.40.2.1. PubMed PMID: 26931748; PubMed Central PMCID: PMC4879970.
17. Gwadry-Sridhar FH, Manias E, Zhang Y, Roy A, Yu-Isenberg K, Hughes DA, et al. A framework for planning and critiquing medication compliance and persistence research using prospective study designs. *Clin Ther.* 2009;31(2):421-35. doi: 10.1016/j.clinthera.2009.02.021. PubMed PMID: 19302915.
18. Hutchins DS, Zeber JE, Roberts CS, Williams AF, Manias E, Peterson AM, et al. Initial Medication Adherence-Review and Recommendations for Good Practices in Outcomes Research: An ISPOR Medication Adherence and Persistence Special Interest Group Report. *Value Health.* 2015;18(5):690-9. doi: 10.1016/j.jval.2015.02.015. PubMed PMID: 26297098.
19. Peterson AM, Nau DP, Cramer JA, Benner J, Gwadry-Sridhar F, Nichol M. A checklist for medication compliance and persistence studies using retrospective databases. *Value Health.* 2007;10(1):3-12. doi: 10.1111/j.1524-4733.2006.00139.x. PubMed PMID: 17261111.
20. Williams AB, Amico KR, Bova C, Womack JA. A proposal for quality standards for measuring medication adherence in research. *AIDS Behav.* 2013;17(1):284-97. doi: 10.1007/s10461-012-0172-7. PubMed PMID: 22407465; PubMed Central PMCID: PMC3434290.
21. Schulz KF, Altman DG, Moher D, Group C. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ.* 2010;340:c332. doi: 10.1136/bmj.c332. PubMed PMID: 20332509; PubMed Central PMCID: PMC2844940.
22. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. *BMJ.* 2007;335(7624):806-8. doi: 10.1136/bmj.39335.541782.AD. PubMed PMID: 17947786; PubMed Central PMCID: PMC2034723.
23. Pinnock H, Barwick M, Carpenter CR, Eldridge S, Grandes G, Griffiths CJ, et al. Standards for Reporting Implementation Studies (StaRI) Statement. *BMJ.* 2017;356:i6795. doi: 10.1136/bmj.i6795. PubMed PMID: 28264797; PubMed Central PMCID: PMC5421438.
24. Cobo E, Cortes J, Ribera JM, Cardellach F, Selva-O'Callaghan A, Kostov B, et al. Effect of using reporting guidelines during peer review on quality of final manuscripts submitted to a biomedical journal: masked randomised trial. *BMJ.* 2011;343:d6783. doi: 10.1136/bmj.d6783. PubMed PMID: 22108262; PubMed Central PMCID: PMC3222149.
25. Kane RL, Wang J, Garrard J. Reporting in randomized clinical trials improved after adoption of the CONSORT statement. *J Clin Epidemiol.* 2007;60(3):241-9. doi: 10.1016/j.jclinepi.2006.06.016. PubMed PMID: 17292017.
26. Moher D, Jones A, Lepage L, Group C. Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. *JAMA.* 2001;285(15):1992-5. PubMed PMID: 11308436.
27. Plint AC, Moher D, Morrison A, Schulz K, Altman DG, Hill C, et al. Does the CONSORT checklist improve the quality of reports of randomised controlled trials? A systematic review. *Med J Aust.* 2006;185(5):263-7. PubMed PMID: 16948622.
28. Turner L, Shamseer L, Altman DG, Schulz KF, Moher D. Does use of the CONSORT Statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review. *Syst Rev.* 2012;1:60. doi: 10.1186/2046-4053-1-60. PubMed PMID: 23194585; PubMed Central PMCID: PMC3564748.
29. Moher D, Schulz KF, Simera I, Altman DG. Guidance for developers of health research reporting guidelines. *PLoS Med.* 2010;7(2):e1000217. doi: 10.1371/journal.pmed.1000217. PubMed PMID: 20169112; PubMed Central PMCID: PMC2821895.
30. Helmy R, Zullig LL, Dunbar-Jacob J, Hughes DA, Vrijens B, Wilson IB, et al. ESPACOMP Medication Adherence Reporting Guidelines (EMERGE): a reactive-Delphi study protocol. *BMJ Open.* 2017;7(2):e013496. doi: 10.1136/bmjopen-2016-013496. PubMed PMID: 28188154; PubMed Central PMCID: PMC5306508.

31. Hoffmann TC, Glasziou PP, Boutron I, Milne R, Perera R, Moher D, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. *BMJ*. 2014;348:g1687. doi: 10.1136/bmj.g1687. PubMed PMID: 24609605.
32. Brown BB, Corporation R. Delphi Process: A Methodology Used for the Elicitation of Opinions of Experts: Rand Corporation; 1968.
33. Salkind NJ. Encyclopedia of measurement and statistics: SAGE Publications; 2007.
34. Powell BJ, Waltz TJ, Chinman MJ, Damschroder LJ, Smith JL, Matthieu MM, et al. A refined compilation of implementation strategies: results from the Expert Recommendations for Implementing Change (ERIC) project. *Implement Sci*. 2015;10:21. doi: 10.1186/s13012-015-0209-1. PubMed PMID: 25889199; PubMed Central PMCID: PMC4328074.
35. van Driel ML, Morledge MD, Ulep R, Shaffer JP, Davies P, Deichmann R. Interventions to improve adherence to lipid-lowering medication. *Cochrane Database Syst Rev*. 2016;12:CD004371. doi: 10.1002/14651858.CD004371.pub4. PubMed PMID: 28000212.
36. Al-Aqeel S, Gershuni O, Al-Sabhan J, Hiligsmann M. Strategies for improving adherence to antiepileptic drug treatment in people with epilepsy. *Cochrane Database Syst Rev*. 2017;2:CD008312. doi: 10.1002/14651858.CD008312.pub3. PubMed PMID: 28157274.
37. Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. *Annu Rev Pharmacol Toxicol*. 2012;52:275-301. doi: 10.1146/annurev-pharmtox-011711-113247. PubMed PMID: 21942628.
38. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. Adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. *BMJ*. 2008;336(7653):1114-7. doi: 10.1136/bmj.39553.670231.25. PubMed PMID: 18480115; PubMed Central PMCID: PMC2386633.
39. Google.com. Google Scholar: Vrijens: A new taxonomy for describing and defining adherence to medications. [Access date: 30.04.2018]. Available from: https://scholar.google.com/scholar?cites=10784671351359133004&as_sdt=2005&scioldt=0,5.
40. Adler AJ, Martin N, Mariani J, Tajer CD, Owolabi OO, Free C, et al. Mobile phone text messaging to improve medication adherence in secondary prevention of cardiovascular disease. *Cochrane Database Syst Rev*. 2017;4:CD011851. doi: 10.1002/14651858.CD011851.pub2. PubMed PMID: 28455948.

TABLE 1: ESPACOMP Medication Adherence Reporting Guideline (EMERGE)

Section	Item No	Recommendation	Reported on page No. / line No.
Minimum reporting criteria			
	1a	Phases of medication adherence: State the phase(s) of medication adherence studied (i.e. initiation, implementation, or persistence) and justify, where possible, the reasons the study focuses on the chosen phase(s).
	1b	Operational definition: Provide the precise operational/working definition for each (of the) phase(s) of medication adherence studied (i.e., initiation, implementation, or persistence).
	1c	Measurement: Specify the method(s) of medication adherence measurement (e.g., self-report, claims data, blood sampling, electronic monitoring). Consider each phase studied (i.e., initiation, implementation, or persistence), with details on the performance of the measure(s) (e.g., validity, reliability, potential bias), where applicable.
	1d	Results: Describe the results of the analysis appropriate to each (of the) phase(s) of medication adherence studied (i.e., initiation, implementation, or persistence).
Abstract			
	2a	Present in the abstract, in as much detail as space permits, information on the 4 minimum reporting criteria (i.e., items 1.1 - 1.4).
Background/introduction			
	3a	Summarize what is known about the topic with appropriate reference to the phase(s) of medication adherence (i.e., initiation, implementation, and persistence).
	3b	Describe the rationale and/or framework guiding the medication adherence study (e.g., theoretical framework, implementation science model).

Study objectives or hypotheses			
	4a	State the study objectives or hypotheses with reference to the phase(s) of medication adherence studied and context (patient population and setting).
Methods			
Design & participants	5a	Describe the setting in which the study was conducted. Refer to factors relevant to medication adherence, such as characteristics of the healthcare system, the healthcare organization, and the healthcare team.
	5b	State whether medication adherence was an eligibility criterion (e.g., inclusion/exclusion). If so, define the measures and rules used.
	5c	Describe routine care related to the management of medication adherence (e.g., routine assessment of medication adherence, adherence support programs, provider training), if applicable.
Measurement	<i>PLEASE REFER TO ITEM 1.C. IN ADDITION TO THE "MEASUREMENT" ITEM BELOW</i>		
	6a	Measurement methods can themselves impact medication adherence (e.g., questionnaires, blood sampling, electronic monitoring). Address this problem as appropriate.
Intervention (where applicable)	7a	For intervention and comparator groups, describe each relevant level of the medication adherence intervention (e.g., healthcare system, healthcare organization, healthcare provider, patient/caregiver).
	7b	Describe any implementation strategy that contributes to the translation (e.g., uptake, delivery, sustainability) of the medication adherence intervention in clinical practice, if applicable.
Statistical analysis	8a	If medication adherence is an outcome variable, justify the statistical methods, given the characteristics of the variable (e.g., phases of medication adherence, data type, statistical distribution, data censoring, longitudinal dependence).
	8b	If medication adherence is an explanatory variable, describe how it is related to the outcome(s) (e.g., causal pathway, temporal sequence).


Results

PLEASE REFER TO ITEM 1.D IN ADDITION TO THE “RESULTS” ITEMS BELOW

- | | | |
|----|---|-------|
| 9a | Determine whether non-participation and/or dropout are associated with non-adherence, and provide any relevant data. | |
| 9b | Present sample characteristics relevant to medication adherence (e.g., socio-demographic, therapy-related, condition-related, patient-related, caregiver-related, healthcare team/healthcare system-related). | |

Discussion

- | | | |
|-----|--|-------|
| 10a | Discuss study strengths and limitations with reference to the phase(s) of medication adherence, where applicable (i.e., initiation, implementation, persistence). | |
| 10b | Discuss the study findings in the context of existing medication adherence evidence (e.g., theory, measurement, intervention effects). | |
| 10c | Discuss the generalizability (external validity) of the study findings with reference to the phase(s) of medication adherence, where applicable (i.e., initiation, implementation, persistence). | |



Based on Vrijens et al. 2012. Br J Clin Pharmacol.(10)

FIGURE 1: Conceptualization of medication adherence